Related references
Note: Only part of the references are listed.The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elias Campo et al.
BLOOD (2022)
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Franck Morschhauser et al.
BLOOD (2021)
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
Frederick J. Kohlhapp et al.
CANCER DISCOVERY (2021)
Randomized Phase II/III Study of DA-EPOCH-R plus /- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
Jeremy S. Abramson et al.
BLOOD (2021)
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Sarah C. Rutherford et al.
LANCET HAEMATOLOGY (2021)
The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
Marcos Garcia-Lacarte et al.
CANCERS (2021)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma
Leo Meriranta et al.
BLOOD ADVANCES (2020)
Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma
Daisuke Ennishi et al.
CANCER DISCOVERY (2020)
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
Hanna Scholze et al.
BLOOD ADVANCES (2020)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Marien Pascual et al.
BLOOD (2019)
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Sema Kurtulus et al.
IMMUNITY (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
Annette M. Staiger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
S. L. Khaw et al.
LEUKEMIA (2014)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Pathogenesis of Human B Cell Lymphomas
Arthur L. Shaffer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers
Dinis Pedro Calado et al.
NATURE IMMUNOLOGY (2012)
Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma
Dinis Pedro Calado et al.
CANCER CELL (2010)
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma:: an international collaborative study
Ken H. Young et al.
BLOOD (2008)
Apoptotic signaling by c-MYC
B. Hoffman et al.
ONCOGENE (2008)
BCL2 protein expression parallels its mRNA level in normal and malignant B cells
YL Shen et al.
BLOOD (2004)
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
SD Catz et al.
ONCOGENE (2001)
Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 is bypassed during lymphomagenesis
CM Eischen et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression
M Grossmann et al.
EMBO JOURNAL (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
